Stocks · Health care · Pharmaceutical Preparations

Milestone Pharmaceuticals Inc.

MIST Clue Score21
Quebec, Canada Fiscal year ends December CIK 0001408443 Results filed 12 Aug 2026

What the insiders did Net buying

By person

16 insiders · 51 transactions
1.5×

Joseph Oliveto holds only 1.5 times base salary in stock. $1.01M of shares against $649.64K in salary for 2025.

Salary from the company's own proxy. The shares are what Joseph Oliveto last reported holding, valued at $2.26, the price Common Shares was last bought or sold at on the open market here, on 16 Apr 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Rtw Investments, LP entity
10% owner
$36.52M (14)
$13.56M (1)
+$22.96M
7,571,204
$17.11M
+75.5%
Bdc Capital Inc. entity
10% owner
$3.00M (1)
—
+$3.00M
2,388,088
$5.40M
+9.1%
De Solidarite Des Travailleurs Du Quebec Fonds
10% owner
$6.50M (1)
$4.32M (2)
+$2.18M
2,254,920
$5.10M
+2,552%
Novo Holdings A/S entity
10% owner
$5.00M (1)
$3.84M (1)
+$1.16M
2,434,470
$5.50M
—
Joseph Oliveto
President and CEO
—
$555.68K (5)
−$555.68K
446,244
$1.01M
+63.4%
Amit Hasija
CFO & EVP of Corp. Development
—
$158.21K (2)
−$158.21K
99,848
$225.66K
—
Jeffrey Edward Nelson
Chief Operating Officer
—
$158.21K (2)
−$158.21K
49,848
$112.66K
—
Lorenz Muller
Chief Commercial Officer
—
$145.85K (2)
−$145.85K
205,406
$464.22K
+314.0%
David Bharucha
Chief Medical Officer
$47.41K (2)
$158.21K (2)
−$110.80K
113,181
$255.79K
—
Michael John Tomsicek
Director
$79.80K (1)
—
+$79.80K
15,000
$33.90K
—
Robert James Wills
Director
$73.95K (1)
—
+$73.95K
65,000
$146.90K
—
Debra K. Liebert
Director
$73.94K (2)
—
+$73.94K
20,793
$46.99K
—
Richard C Pasternak
Director
$52.00K (1)
—
+$52.00K
10,000
$22.60K
—
Paul F Truex
Director
$28.00K (1)
—
+$28.00K
81,780
$184.82K
—
Joseph C Papa
Director
—
—
—
100,000
$226.00K
—
Philippe Douville
Chief Scientific Officer
—
—
—
43,392
$98.07K
+10.5%

No percentages here. This company's share count has moved by a factor of 2.3 over the window, from 53,353,984 to 124,497,980 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.